Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021
Osmotica Pharmaceuticals (Nasdaq: OSMT) will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:00 a.m. Eastern Time. CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn will lead the presentation, which will be available via live webcast and archived for 30 days on Osmotica’s website. The company focuses on developing and commercializing products for underserved patient populations, with their recent launch of UPNEEQ, approved for treating droopy eyelids in adults.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was -1.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:
| Date: | Monday, September 27, 2021 | |
| Time: | 10:00 a.m. Eastern Time | |
| Webcast: | https://wsw.com/webcast/cantor12/osmt/2117150 | |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations. In July 2020, the Company received regulatory approval from the U.S Food and Drug Administration for RVL-1201, or UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution),
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.